Clinical trials: Gastroesophageal-junction Cancer
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated Chinese adults with gastric and gastroesophageal…
- Trial name
- NCT04882241
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 20 sites in China
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following…
- Trial name
- NCT02443883
- Testing
- Ramucirumab
- Where
- 45 sites in United States, Argentina and 10 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with…
- Trial name
- HELOISE (NCT01450696)
- Testing
- Capecitabine, Cisplatin, Herceptin
- Where
- 117 sites in United States, Australia and 23 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body…
- Conditions
- Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma
- Trial name
- NCT01142388
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 232 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Gastric Cancer, Gastroesophageal Junction Cancer
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- CheckMate649 (NCT02872116)
- Testing
- Nivolumab, Ipilimumab, Oxaliplatin
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 2,031 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Cancer
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT00539617
- Testing
- Erlotinib, 5-fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT00064259
- Testing
- oblimersen sodium, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Stomach, Gastroesophageal Junction Expressing Guanylyl Cyclase C
A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.
- Trial name
- NCT02202759
- Testing
- MLN0264
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 38 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
RATIONALE: Pralatrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT01129206
- Testing
- pralatrexate, docetaxel, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Esophageal Cancer
Trimodality Management of T1b Esophageal Cancers
The goal of this clinical research study is to learn if giving chemotherapy and radiation therapy before surgery for early-stage esophageal cancer can help to control the disease and if so, for how long.
- Trial name
- NCT01217060
- Testing
- Docetaxel, 5-FU, Radiotherapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
This phase IB/II trial studies the side effects of taladegib, paclitaxel, carboplatin, and external beam radiation therapy and to see how well they work in treating patients with esophageal or gastroesophageal junction cancer…
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7, Stage II Esophageal Adenocarcinoma AJCC v7, Stage IIA Esophageal Adenocarcinoma AJCC v7
- Trial name
- NCT02530437
- Testing
- Carboplatin, External Beam Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer, Gastric Cancer
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
- Trial name
- NCT00439608
- Testing
- Cetuximab,Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brown University
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal…
- Trial name
- NCT03221426
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 171 sites in United States, Belgium and 22 more
- Volunteers
- 1,007 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer, Gastric Adenocarcinoma
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
This study is to determine whether intraperitoneal (IP) Floxuridine is effective in the patients with advanced stomach or gastro-esophageal junction cancers in the treatment consisting of pre- and post-surgery chemotherapies.
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00848783
- Testing
- Irinotecan, Cisplatin, Surgery
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
Advanced Cancer
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
- Trial name
- CheckMate 577 (NCT02743494)
- Testing
- Nivolumab
- Where
- 204 sites in United States, Argentina and 29 more
- Volunteers
- 794 people
- Sponsor
- Bristol-Myers Squibb
HER-2 Gene Amplification, Esophagus Cancer
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Trial name
- NCT01774851
- Testing
- MM-111, Paclitaxel, Trastuzumab
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- Merrimack Pharmaceuticals
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT01333033
- Testing
- Oxaliplatin, Leucovorin Calcium, Fluorouracil
- Where
- 68 sites in United States
- Volunteers
- 257 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Esophageal Cancer
Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
The interaction of epidermal growth factor receptor (EGFR) inhibitory agents such as cetuximab combined with radiation shows promising results.
- Trial name
- NCT00319735
- Testing
- Radiation Therapy, Surgery, Tissue Sample
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Nasser Hanna, M.D.